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Abstract 
 
When exposed to resistance exercise, untrained muscle can develop micro-tears and disruptions 
in the sarcomeres.  This is followed by swelling, pain and decreased muscle performance, which 
can be attenuated by taking β-hydroxy-β-methylbutyrate (HMB).  The acute phase response is 
the inflammatory change that occurs to repair damaged tissue, and is mediated by cytokines.  It 
is the purpose of this study to determine if HMB can influence the acute phase response.  32 
untrained subjects (16 men, 16 women) completed three sets of 50 eccentric leg extensions on 
each leg.  The subjects were group matched and randomly assigned to one of three treatment 
groups: placebo (CON), HMB pre exercise (PRE) or HMB pre-exercise and for 4 days following 
the exercise protocol (PRE-POST).  We observed a drop in serum concentration of IL-1ra and 
TNF-α for the CON, that was attenuated by HMB at 48h and 72h post exercise (p<.05).  The 
observed reduction in acute phase response suggests that HMB may moderate inflammatory 
response to exercise induced muscle damage. 
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Manuscript 
Introduction 
When untrained muscle is exposed to intense exercise, there is the potential to cause physical 
damage to the myofibers as demonstrated by sarcomere disruption (18) and myosin contractile 
protein leakage (61).  The amount of damage is larger following eccentric contractions than 
concentric contractions and is associated with decreased range of motion (ROM) and peak 
force(19).  Delayed onset muscle soreness (DOMS) occurs 24-72 h after the exercise and 
correlates with increases in plasma creatine phosphokinase (CK), lactate dehydrogenase (LDH) 
and 3-methyl histidine (3-MH) (41). 
Following a damaging bout of exercise, inflammation sets in to repair damaged tissue.  
Inflammation is mediated chemically by several cytokines.  Interleukin (IL) 1 beta (IL-1β) and 
tumor necrosis factor alpha (TNF-α) have been linked to increased proteolysis and may 
modulate protein turnover (11).  IL-1β, TNF-α, and IL-6 are commonly regarded as pro-
inflammatory cytokines because they initiate and amplify immune cell function.  Anti-
inflammatory cytokines (IL-10 and IL-1 receptor antagonist (IL-1ra)) work to regulate and 
resolve the inflammatory response. 
The inflammatory response to strenuous endurance exercise has been examined previously, but 
the response to eccentric induced damage has returned mixed results.  One study used elbow 
flexors and found increases in serum increases in IL-6 and IL-1ra (50), but another failed to find 
any rise with a similar protocol (22).  It is possible that using the elbow flexors does not induce 
enough damage to increase serum levels to detectable differences.  It is also possible that tissue 
accumulation of the cytokines occurs to limit serum increases (6, 13).  Buford et al. (4) was 
unable to detect serum levels of TNF-α, IL-1β, or IL-6 following leg resistance training but did 
find increases in the mRNA for those cytokines, signifying an up-regulation that was not 
detected in the serum. 
The amount of inflammation is dependent upon the intensity of the bout, and training status.  
Trained subjects have higher resting cytokine levels, but do not have the up-regulation following 
a single bout experienced by untrained subjects (12).  Repeated bouts also results in less muscle 
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damage as found by serum CK(9).  In addition to training, β-hydroxy-β-methylbutyrate (HMB) 
may decrease the amount of muscle damage caused by exercise induced muscle damage 
(EIMD)(9).  HMB is a leucine metabolite taken as a supplement and is associated with less 
proteolysis (58), reduced 3-MH, CK and LDH (38) following a bout of resistance training in 
untrained subjects.  It is believed that increased availability of HMB, a de novo cholesterol 
synthesis precursor, increases the membrane integrity of skeletal muscle (57). 
Increased muscle integrity and decreased muscle breakdown allows the muscle to experience less 
EIMD and recover faster.  HMB has the potential to reduce the amount of inflammation that 
occurs.  It is the goal of this study to examine the inflammatory response to EIMD by using 
eccentric leg extension and to determine if HMB is able to reduce the amount of inflammation 
that accrues. 
 
Methods 
Subjects.  Sixteen females and 16 males volunteered to participate in this study.  The mean ±SE 
of the age, body mass and height were as follows: 23±0.30y, 67.5±0.9kg, and 172.2±0.7cm (table 
1.).  All subjects were free from injury and illness as determined by a medical questionnaire.  
None of the subjects had engaged in resistance training in the 3 months prior and were not 
taking any dietary supplements.  They were advised to refrain from exercising outside of the 
protocol and to not consume anti-inflammatory medication (NSAID, etc.).  They were also 
provided a list of foods high in 3-MH, that they were advised not to consume.  Written 
informed consent was given to subjects prior to their involvement.  This study was approved by 
the Iowa State University IRB. 
Table 1. Age, Height and Mass.  Mean (SEM). 
 N AGE (y) Ht. (cm) Mass (Kg) 
CON 6 24 (2) 172 (3) 66.1 (4.9) 
PRE 13 22 (1) 171 (4) 66.8 (3.4) 
PRE/POST 13 24 (1) 173 (3) 68.8 (3.4) 
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Experimental protocol.  Prior to the start, subjects came to the lab for a familiarization trial.  They 
were measured for maximal isometric force on both legs.  Maximal isometric leg extension was 
performed for 3 repetitions for 5 sec. each with 5 sec. rest between repetitions at an angle of 
110°.  Subjects were randomly assigned to 5 experimental groups and experimental groups were 
matched based on dominate leg average peak force so that the average between groups was the 
same. 
Muscle damage and inflammatory response was determined with the following indicators: 
maximal isometric force, muscle soreness, mid-thigh leg circumference, urinary 3-MH, serum 
CK, LDH, IL-1ra, IL-1β, C-reactive proteins (CRP), IL-6, and TNF-α.  All measures were taken 
in the morning (5am-9am) at the same time day for each subject.  Subjects were fasted (12 h) but 
allowed water.  Maximal isometric force was taken 30 min after the morning supplement.  The 
remaining measures were collected prior to the supplement.  Measures were performed before 
the exercise protocol and for the 4 days following the exercise protocol.  A chart outlining the 
procedure is displayed in Table 3. 
Supplementation/Experimental groups.  Supplementation was given 3 times throughout the day.  The 
first occurred early morning in the lab under supervision and the remaining two occurred at mid 
day and evening time points.  Supplements came in two forms, a capsule of HMB calcium salt, 
and a 3ml gel syringe of HMB free acid, both taken orally.  Subjects were advised to consume 
the capsule, then the gel, and then 500ml of water.  Empty syringes were collected to ensure 
compliance. 
Experimental groups received supplement in one of the following manners: placebo pre- & 
post-exercise (CON), HMB pre-exercise (PRE) in either a calcium salt form or a free acid gel, 
HMB pre- & post-exercise (PRE/POST)in either a calcium salt form or a free acid gel.   
Supplements were given in a double-blind protocol so that investigators were also blind to the 
contents of the supplements throughout the study.  Originally, the study called for 5 treatment 
groups with a separation of calcium salt groups from the free acid gel groups.  Due to sample 
sizes, groups receiving the same quantity of HMB were consolidated for statistical reasons (see 
Table2.) 
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Table 2. Consolidation of groups. Treatment group name and type of HMB supplement. 
 
Table 3. Experimental Protocol. 
 
Muscle Soreness/Leg circumference.  Muscle soreness was determined by a visual analog scale (43).  A 
10 cm horizontal line was presented with “no pain” at one end and “extreme pain” on the other.  
Subjects would draw a vertical line along the horizontal to establish the degree of muscle 
soreness.  Mid-thigh leg circumference was measured by tape measure half-way between the 
inguinal crest and top of the patella while subjects were seated and relaxed with knees flexed at 
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90°.  Measurement sites were labeled with semi-permanent marker, and all measurements were 
taken by the same investigator. 
Exercise protocol.  Subjects were seated and performed 3 sets of 50 eccentric leg extensions on 
both legs.  The leg extensions went from 0° to 90° at a rate of 60°/sec.  Each repetition took 
approximately 3 sec. to complete and contraction occurred on the downward swing only.  
Subjects were given 2 min rests between sets. 
Cytokines.  Whole blood was collected into two 10 ml glass tubes and allowed to coagulate for at 
least 30 min at RT before being centrifuged at 2,800 rpm for 10 min.  Serum was manually 
extracted by pipette and separated into 600 μl aliquots.  Samples were stored at -80°C until 
analysis and all measures were taken to limit freeze-thaw cycles.  Cytokines measured were IL-6, 
IL-1β, IL-1ra, TNF-α, and CRP.  All samples were measured in duplicates and all time points for 
a given subject were analyzed on the same plate.  Serum cytokines were measured using 
commercially available enzyme linked immunosorbent assays (ELISA; R&D Systems, R&D 
Systems, Minneapolis, MN, USA).  High sensitivity kits were used for TNF-α, IL-6 and IL-1β. 
Statistical Analysis.  All measured samples were tested using a repeated measures ANOVA.  The 
p-value for significance was set at 0.05.  Analysis of the deltas from baseline were analyzed for 
IL-6, IL-1ra, TNF-α and CRP. 
Results 
Muscle soreness, leg circumference, peak leg force.  Peak muscle soreness for all groups was reached 48h 
after the exercise bout with a 1200% increase in perceived muscle soreness.  There was no 
difference in muscle soreness found between treatment groups.  Leg circumference was 
unchanged over time and there was no difference between treatment groups.  The decrease in 
peak leg force of the right leg peaked at 72h post-exercise and decreased by 10.5% from pre-
exercise to 72h post-exercise (p-value = 0.008).  The decrease in peak leg force of the left leg 
peaked at 48h post-exercise and decreased by 10.5% (p-value = 0.023).  No difference in the loss 
of peak force was found between the treatment groups. Results are displayed in table 4, and 
figures 4 & 5. 
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CK, 3-MH, LDH.  Serum CK concentration peaked at 96h post exercise (p= 0.037) for all three 
treatment groups (CON = 3487.5 U/ml, PRE = 4067.6 U/ml, PRE/POST = 1592.6 U/ml).  
There was no difference in peak CK between treatment groups.  Peak serum LDH was reached 
at 72h post-exercise (p= 0.022) but no difference was found between groups (CON = 269.8 
U/ml, PRE = 212.7 U/ml, PRE/POST = 180.9 U/ml).  3-MH was not significantly different 
between groups and failed to show a time effect. Results are displayed in table 4. 
IL-1β and IL-6.  The concentration of IL-1β, for most subjects, was below detection minimums.  
Therefore we were unable to obtain reliable data regarding this cytokines.  IL-6 showed no 
change over time and there was not an observed difference between groups (table 4). 
TNF-α, CRP, IL-1ra.  The change in serum concentration of IL-1ra, as shown in figure 1, was 
significantly different from the control group at 48h (PRE p= 0.007, PRE/POST p= 0.038) and 
72h (PRE p= 0.005, PRE/POST p= 0.040) for both treatment groups, with PRE/POST 
remaining elevated at 96h as well (p= 0.018).  Serum concentration of CRP was elevated from 
baseline with PRE group at 48h (p= 0.002), 72h (p= 0.019), and 96h (p= 0.048), but failed to 
show any significant difference between the other treatment groups.  A graph of the change in 
CRP is displayed in figure 2.A decrease in serum TNF-α within the control group is shown in 
figure 3.  The treatment attenuated the depression and was significantly different from CON at 
48h (PRE/POST p= 0.047) and 72h (PRE p= 0.010, PRE/POST p= 0.008). 
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Figure 1. Change in IL-1ra.  CON vs. PRE/POST (†, p≤0.05), CON vs. PRE (‡, p≤0.05). 
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Figure 2. Change in CRP.  Different from baseline (*, p≤0.05). 
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Figure 3. Change in TNF-α.  CON vs. PRE/POST (†, p≤0.05), CON vs. PRE (‡, p≤0.05). 
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Figure 4.  Left leg average peak force.  Different from baseline (*, p≤0.05). 
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Figure 5. Muscle soreness scale. Different from baseline (*, p≤0.05). 
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Table 4.  Serum concentrations and markers of muscle damage.  CON vs. PRE/POST (†, p≤0.05); CON vs. PRE (‡, 
p≤0.05); Different from baseline ( 1, p≤0.05); different from 96h ( 2, p≤0.05); Different form 72h ( 3, p≤0.05). 
    Pre 24 48 72 96 SEM 
IL-1ra (pg/ml) 
CON 279.5 241.0 212.6 198.5 215.9 43.2 
PRE 161.9 191.3 188.5 173.5 176.4 29.3 
PRE/POST 189.4 212.5 246.2 236.7 236.0 29.3 
d IL-1ra 
CON 0.0 -38.4 -66.9 -81.0 -63.5 32.2 
PRE 0.0 29.4 26.6‡ 11.6‡ 14.4 21.9 
PRE/POST 0.0 23.1 56.9† 47.4† 46.6† 21.9 
TNF-a (pg/ml) 
CON 1.62 1.45 1.30 1.30 1.61 0.24 
PRE 1.49 1.50 1.41 1.56 1.56 0.17 
PRE/POST 1.03 1.12 1.03 1.10 1.17 0.17 
d TNF-a 
CON 0.00 -0.17 -0.33 -0.32 -0.02 0.11 
PRE 0.00 0.02 -0.08 0.07‡ 0.07 0.07 
PRE/POST 0.00 0.09 0.00† 0.07† 0.14 0.07 
IL-6 (pg/ml) 
CON 0.99 0.92 1.13 1.13 1.38 0.28 
PRE 1.16 1.23 1.26 0.97 0.89 0.19 
PRE/POST 0.95 0.99 0.93 1.21 1.10 0.19 
d IL-6 
CON 0.00 -0.07 0.14 0.14 0.39 0.25 
PRE 0.00 0.07 0.10 -0.19 -0.27 0.17 
PRE/POST 0.00 0.04 -0.02 0.26 0.14 0.17 
CRP (pg/ml) 
CON 1088.5 1166.5 1203.3 1252.7 1311.2 576.5 
PRE 1219.8 2046.7 1885.1 1810.2 1659.3 391.7 
PRE/POST 1143.4 1450.1 1308.0 1360.0 1368.2 391.7 
d CRP 
CON 0.0 78.0 114.8 164.2 222.7 342.0 
PRE 0.0 826.91 665.31 590.41 439.5 232.3 
PRE/POST 0.0 306.7 164.6 216.5 224.8 232.3 
CK (U/ml) 
CON 170.8 395.3 1956.3 3513.8 3487.5 1503.3 
PRE 113.0 449.4 1121.5 2907.2 4067.6 1021.3 
PRE/POST 169.2 424.2 1025.7 1495.9 1592.6 984.1 
LDH (U/ml) 
CON 145.4 150.8 229.3 269.8 242.2 37.2 
PRE 145.9 153.7 167.8 212.7 222.9 25.3 
PRE/POST 138.3 146.7 163.8 180.9 177.6 24.3 
3-MH (nmol/ml) 
CON 169.7 219.5 176.7 126.0 163.5 32.0 
PRE 193.9 207.7 150.9 210.4 138.6 21.7 
PRE/POST 210.9 203.9 163.8 175.5 157.2 20.9 
R-leg Peak Force (N) 
CON 188.9 173.2 174.9 158.6 190.9 25.2 
PRE 216.6 194.3 196.5 197.6 203.1 17.1 
PRE/POST 210.5 197.9 196.8 195.0 209.2 17.1 
L-leg Peak Force (N) 
CON 178.5 159.7 153.1 178.1 183.1 24.3 
PRE 185.1 179.9 174.1 192.8 195.5 16.5 
PRE/POST 203.0 187.0 180.0 193.4 198.9 16.5 
Muscle Soreness (mm) 
CON 0.23 5.771,2 5.951,2 4.131 2.401 0.78 
PRE 0.44 5.421,2 5.991,2 4.651,2 1.71 0.53 
PRE/POST 0.32 5.321,2,3 5.471,2,3 3.721,2 1.881 0.53 
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Discussion 
The objective of this study was to determine the effect of HMB on the inflammatory response 
to EIMD.  HMB has been shown to improve recovery and decreases damage to muscle cells 
after intense exercise, especially in untrained subjects.  It was predicted that HMB will reduce the 
magnitude of an inflammatory response to EIMD and the results provide evidence for a 
decrease in serum TNF-α and IL-1ra after exercise, which is not observed with HMB 
supplementation.  These findings occurred despite no difference in CK and LDH, common 
indicators of muscle damage, between groups. 
The largest limitation of this study was the low subject number, particularly with the CON group 
which had just half the number of subjects of each of the other two treatment groups.  Time and 
economic constraints dictated our sample size.  Also, due to the large variability of the markers 
used in this study, a large sample size is needed to establish statistical significance between the 
small variations observed.  High sensitivity tests were used when available to ensure the best 
results. 
There were several outcomes that were expected but not observed.  We did not observe any 
difference between groups with regards to CK, LDH and 3-MH.  Circulating concentrations of 
these muscle damage indicators have been shown to be reduced with HMB (38).  In terms of 
CK, we did not detect nearly the same peak in the PRE/POST compared to PRE and CON, but 
it was not significant.  PRE/POST peaked at 1593 IU compared to 3514 IU and 4068 IU in the 
CON and PRE groups respectively.  The trend suggests less damage if HMB is given before and 
after the bout, and it is believed that with larger sample sizes that would have more evident.  The 
decrease in right leg peak force was about 16% in the CON group compared to 9% and 7% in 
the PRE and PRE/POST groups, respectively.  This difference was not significant but does 
suggest a trend towards a smaller loss of function.  Muscle soreness was also not significantly 
different between groups, which has been supported by other studies (44), but both PRE and 
PRE/POST appear as if they may be closer to baseline at 96h than CON.  In addition to sample 
size, the degree of muscle damage may have impacted our findings.  A previous study (36) 
reported CK and LDH as high as 17,000 U/ml and 580 U/ml, respectively.  Our results did not 
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reach those levels and it is possible that the amount of EIMD induced was insufficient to create 
a detectable change in the serum concentrations of CK and LDH. 
Following a bout of resistance exercise, several studies have shown cytokines have a transient 
rise immediately after and return to pre-exercise levels by 24h (12, 24, 32, 50, 69), while others 
reported no change in serum cytokines detected (4, 22, 41).  Only a few studies have shown 
elevated levels in the serum after +24h post-exercise (52, 60).  During these first 24h following 
exercise, urine output of cytokines increases but is transient as well (62).  Even without observed 
changes in serum concentrations, it is possible that cytokine production is enhanced as a 
previous study reported mRNA for TNF-α, IL-1β and IL-6 to be up-regulated without the 
subsequent serum rise (4). 
Our results showed a decrease in TNF-α and IL-1ra with the CON group.  The depression in 
serum cytokines has been documented by other researchers as well.  Hirose et al. (22) observed 
cytokines after eccentric resistance exercises of the elbow flexors.  They reported plasma 
concentrations of TNF-α and IL-8 that were lower than pre-exercise levels for up to 4d.  It is 
possible that the decreased serum cytokine concentration is a result of tissue accumulation.  The 
accumulation of neutrophils, a source of cytokine production, and IL-1β in exercise tissue has 
been reported (6, 13).  The IL-1β in the muscle tissue persisted for up to 5d and correlated to 
structural damage of the myofibers. 
The results of TNF-α and IL-1ra support the theory that inflammation is affected by HMB.  In 
both cases (fig. 1 & 2) the CON group experienced a decline in serum concentration and the dip 
was reduced or limited by supplementation of HMB.  These results could be interpreted as an 
increase in the inflammatory response following HMB supplementation, and is further 
supported by the results of CRP at least in the PRE group.  This suggests that HMB creates a 
greater inflammatory response which may improve recovery of damaged tissue.  When exactly 
this occurs and how, whether direct or indirect, is not evident from this study.  We already know 
that proteolysis is affected by HMB and it is also possible that inflammatory cytokines are 
mediating an optimal recovery.   
For future investigations, it would be beneficial to measure early in the recovery to determine if 
HMB has an impact on the initial and transient rise of cytokines observed by others.  Whether 
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or not IL-6 is affected would help suggest an inflammatory or metabolic response as HMB 
would not influence any metabolic response from a single bout.  Without also identifying 
changes in mRNA or tissue accumulation, it is difficult to determine if HMB has a role in 
cytokine production or tissue accumulation.  It is possible that HMB effects the production of 
both pro and anti-inflammatory cytokines to speed recovery and limit overstimulation of pro-
inflammatory cytokines. 
The goal of this study was to describe the role HMB had on the inflammatory response to a 
stressful bout of exercise.  Our data showed that HMB does suppress the decrease of IL-1ra and 
TNF-α in the serum.  This effect could be a result of cytokine production being influenced by 
HMB, or an indirect result of less damage occurring.  Previous research suggests HMB is 
beneficial to recovery, at least in untrained individuals, and regulating the inflammatory response 
to facilitate optimal recovery could be the process influenced by HMB. 
16 
 
Review of Literature 
Introduction 
During exercise it is possible to cause damage to the cellular structure of muscle fibers.  The 
extent of damage is dependent on the mode of contractions with eccentric causing more damage 
than concentric contractions (19).  This exercise induced muscle damage (EIMD) triggers a 
training adaptation that leads to removal of cellular debris and repair of the disrupted myofibers.  
Trained muscle has adapted to be more resilient and has the ability to withstand exercise of 
higher intensity without subsequent damage.  This process is mediated by the inflammatory 
system.  Chemical regulators, known as cytokines, are generated locally and systemically to 
facilitate the process. 
Training has been shown to decrease the muscle damage and inflammation that occurs during 
resistance exercise bouts (5).  Muscle damage is also reduced by the supplementation of the 
leucine metabolite, β-hydroxy-β-methylbutyrate (HMB) (15, 38).  The use of HMB following 
resistance exercise in which muscle damage occurs has been shown to reduce muscle soreness, 
loss of force production, and increase lean muscle mass.  But the role of HMB on inflammation 
has not yet been investigated. 
HMB, a precursor to de novo cholesterol synthesis,  is believed to increase cholesterol 
availability during the rebuilding process of damaged muscle (57).  HMB is also associated with 
decreased proteolysis following exercise (58).  The decrease in proteolysis and increased 
membrane synthesis when HMB is supplemented, contributes to less damage and faster 
recovery. 
HMB may also influence the inflammatory response to exercise bouts that cause damage.  
EIMD & other intense exercise bouts have been shown to release several inflammatory markers.  
Research on cytokine release following a resistance exercise bout with supplemented HMB is 
very limited.  Due to HMB’s effect on muscle damage, it is the goal of this study to provide 
evidence regarding the role of HMB on the inflammatory response.  It is hypothesized that 
markers of inflammation will be reduced when HMB is taken following an eccentric exercise 
bout. 
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Muscle Damage and Proteolysis 
Exercise-induced muscle damage 
During contraction, muscle sarcomeres shorten.  When the force is too great, the muscle fibers 
becomes stretched and damaged.  This overload is the basis of most exercise training regimens.  
The damaged muscle cells contain micro-tears where the sarcolemma is disrupted.  The ultra-
structure of damaged muscle fibers show disrupted sarcomeres, widening and irregularity of 
cross striations, and Z-band streaming (14, 19, 28). 
The EIMD that occurs is commonly associated with swelling of the tissue, pain, and a rise in 
muscle enzymes and is typically followed by an inflammatory response (1, 10).  EIMD is also 
strongly associated with a decline in force production in the days following(31, 43).  The loss of 
force is believed to be from disrupted excitation-contraction couplings associated with the 
physical separation of myofibrils.  Range of motion (ROM) of the exercised limb has also been 
found to decrease after damaging bouts of exercise(43).  
Delayed onset muscle soreness (DOMS) is commonly seen with EIMD and is identified as the 
pain present 24 to72 hrs after the damaging exercise bout.  DOMS is a subjective indicator of 
muscle damage and its correlation to EIMD is weak, but it is still commonly used to indicate 
some degree of muscle damage.  The magnitude of DOMS and EIMD that is invoked is 
dependent on the load and the number of contractions.  Eccentric contractions occur when 
contraction force is less than the resistance force and the muscle lengthens.  They induce greater 
cell damage than concentric (muscle shortens) or isometric (muscle length stays the same) 
contractions (18, 19, 34).  Many high load eccentric contractions cause the greatest muscle 
damage and subsequent DOMS compared to fewer eccentric contractions. 
The physical separation of the sarcolemma causes gaps in the membrane (1).  Common serum 
markers of muscle damage include creatine phosphokinase (CK), lactate dehydrogenase (LDH), 
and myoglobin (Mb) (9, 41).  These enzymes are found in the muscle tissue, but when damage to 
the sarcolemma occurs they are able to leak out and enter the circulatory system.  Mb is relatively 
small and can enter the blood system directly, so the increase is seen soon after the strenuous 
exercise bout.  But Mb exists in the cytoplasm and indicates membrane leakage not structural 
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damage of contractile units.  CK and LDH are larger and must enter the lymphatic system 
before entering the blood.  This results in a delayed rise and may influence the high variability 
typically found with these markers (43).  Additionally, Nosaka & Clarkson (42) did not find a 
correlation between CK release and the amount muscle mass that was used, which suggest CK 
may be a poor indicator of muscle damage. 
To determine a more ideal marker of muscle damage, several proteins have been investigated.  
Myosin heavy chain (MHC) has been shown to increase with EIMD (61).  MHC is a structurally 
bound contractile protein in muscle.  The increase in MHC suggests both structural damage and 
membrane leakage, but the rise is delayed (~2 d) and not detectable early after the exercise.  
Additionally, MHC has several isoforms that make it difficult to determine if the damage is 
coming solely from skeletal muscle.  Troponin I (TnI) is a contractile protein that is found only 
in muscle tissue.  It has isoforms that exist in cardiac (cTnI) and skeletal (sTnI) muscle cells.  
Sorichter et al. (61) found rises in sTnI after 2-6 h from onset, and remains elevated for 1-2 d. 
Recovery/training 
 Following muscle damage, the cells immediately begin repair.  Muscle proteolysis begins 
to degrade damaged protein prior to adaptation.  Three mechanisms of protein degradation 
occur: lysosomal, calpain activated and ubiquitin activated.  Lysosomal and calpain activated 
protein degradation are broadly based with low specificity.  The ubiquitin pathway is the 
intracellular mechanism for specific protein degradation.  Ubiquitin pathway is stimulated 
following a strenuous exercise bout and is also common during increased muscle proteolysis 
such as during limb immobilization, starvation and de-nervation (54, 58, 59, 74). 
Repeating the same strenuous exercise causes reduced damage with each subsequent bout (9, 
10).  Training decreases the activation of the ubiquitin pathway leading to less proteolysis 
following exercise (75).  The diminished proteolysis is a training response in which the muscle 
cells become more resilient and require less tissue repair.  Resistance training stimulates 
hypertrophy of muscle fibers, hyperplasia, and increased connective tissue surrounding the 
muscle fiber.  The balance between degradation and synthesis is tightly regulated and research 
has suggested the mTOR receptors play a significant role in transcriptional regulation of protein 
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balance.  The mTOR pathway is stimulated following an exercise bout to increase protein 
synthesis. 
Inflammation 
Cytokine action  
Damage to skeletal muscle is followed by an inflammatory response that is geared towards 
removal of damaged tissue.  Increased protein turnover is common in sepsis, trauma and EIMD.  
An acute phase response commonly expresses the following symptoms: heat production, protein 
degradation, fatigue, edema and higher urea excretion.  The regulation of the acute phase is 
mediated by several inflammatory proteins.  These circulating peptides (cytokines) were 
proposed by Clowes et al. (11) when he found a three-fold increase in normal protein turnover 
after plasma from septic patients was introduced to muscle tissue from non-septic subjects. 
Cytokines are released by neutrophils, macrophages, fibroblasts, and damaged muscle cells (7).  
The acute phase response is identified as the systemic change in cytokines that follows a local 
inflammatory response.  It initiates white blood cell (WBC) accumulation after EIMD occurs.  
The WBC accumulation mediates the repair process and is directed towards damaged tissue; 
non-damaged tissue has little to no increase in WBC concentration (31). 
Two common WBC involved with the acute phase response are neutrophils and macrophages.  
Neutrophils enter damaged tissue and are involved with phagocytosis of necrotic myofibers and 
cellular debris (28).  In rat muscle, the neutrophils enter the tissue within 2 h post-exercise and 
are present for up to four days.  Humans have similar response times; neutrophils accumulate as 
quickly as 45 min (13) and persists for up to three days (21).  Macrophages/monocytes enter 
human tissue within one day and are evident for several days after injury (21). 
Sepsis is the most extreme form of inflammation, usually caused by some form of infection.  
Cytokines that have been well documented as increasing during sepsis are interleukin (IL)–1β, 
IL-10, IL-6, IL-1 receptor antagonist (IL-1ra), IL-8, and tumor necrosis factor-α (TNF-α) (67).   
Cytokines are commonly referred as pro-inflammatory or anti-inflammatory.  Pro-inflammatory 
cytokines cause neutrophil aggregation and swelling, and they amplify inflammatory responses.  
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Anti-inflammatory cytokines work against pro-inflammatory cytokines to control and regulate 
the acute phase response. Both types of cytokines are present in serum, but their responsiveness 
is very sensitive and small changes in plasma concentration can elicit large responses. 
Common pro-inflammatory markers seen in the blood are TNF-α and IL-1β.  These pro-
inflammatory cytokines are responsible for many of the acute metabolic responses that occur 
during sepsis and inflammation (11, 20).  Protein turnover is mediated strongly by TNF-α as 
determined by larger 3-MH excretion (20), loss of muscle mass (30) and increased ubiquitin gene 
expression (17).  Additionally, IL-1β in the brain may be a significant contributor to fatigue, 
decreased performance and hyperalgesia following EIMD (8) 
Anti-inflammatory makers typically include IL-4, IL-10 and IL-1 receptor antagonist (IL-1ra).  
IL-1ra specifically acts against the function of type 1 interleukins.  When IL-1ra is given to 
animals, 3-MH excretion is reduced (78).  IL-6 is a cytokine that is commonly referenced as anti-
inflammatory because it triggers production of IL-10 and IL-1ra (3, 65) and may reduce IL-1β 
and TNF-α release with exercise (33, 63).  However, IL-6 has consistently been shown to 
increase due to low grade exercise where exercise induced damage is not believed to occur. 
Cytokines and exercise 
A rise in cytokine levels following marathons and prolonged strenuous exercise has been well-
documented.  This type of exercise has induced elevated plasma levels of IL-1β (35, 47), IL-6 
(35, 45, 64), TNF-α (35, 45, 64), IL-1ra (45, 47), IL-10 (47) , IL-8 and MIP-1β (46).  But the 
physiological response to endurance type exercises and resistance type exercises are very 
different.  Thus it is important to look at how cytokines respond specifically to resistance type 
exercises. 
 The most widely studied cytokine, IL-6, is associated with contracting muscle and increases 
following exercise (51).  IL-6 increases even when muscle damage does not occur and circulating 
levels are increased based on exercise intensity, duration, muscle group, and glucose levels (51).  
The concentration of  IL-6 in the plasma following heavy exercise can be attenuated by 
carbohydrate ingestion (37).  The systemic increase in IL-6 occurs early following exercise with 
studies showing a significant rise immediately after but returning to normal by 24h (32, 50, 69).  
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Additionally, local production of  IL-6 within muscle tissue has been shown to increase with 
active tissue and not inactive tissue (25, 66).  It has been suggested that IL-6 is related to a 
metabolic response, because it occurs in a similar response with both eccentric and concentric 
exercise (25).   
However, IL-6 has been found 2d post eccentric leg extensions (52).  Any metabolic response 
would have been over by that point, so it is possible that under some situations IL-6 does act as 
an anti-inflammatory cytokine.  IL-6 acts to increase IL-1ra, IL-10 and cortisol(65), all of which 
limit production and function of pro-inflammatory cytokines IL-1 and TNF- α (5). 
The anti-inflammatory cytokine, IL-10 has been shown to be elevated (60) and absent (50) 
following strenuous exercise.  A study by Izquierdo et al (24) that looked at the acute response 
and a training effect, found that IL-10 and IL-1ra had a more pronounced acute response after 7 
weeks of resistance training.  It is possible that untrained subjects do not see a rise in anti-
inflammatory cytokines because the tissue has not adapted to repeated bouts and therefore less 
efficient at the repair process.  Another resistance exercise study found increases in IL-1ra 
immediately after exercise but the levels returned to normal by 24h (69). 
Following a bout of eccentric or resistance exercise in which EIMD occurs, there appears to be 
a transient rise in IL-1β that returns to normal by 24h (12, 24).  Following the transient rise in 
pro-inflammatory cytokines in the blood, serum concentrations of TNF-α and IL-1β will show a 
decrease as early as 6h  and may persist for up to 120h (22, 60).  Not all studies show significant 
circulating changes in these cytokines (4, 60, 69).  Corresponding with the transient systemic rise 
of the cytokines, is a rapid clearance in the kidneys (62).  Clearance rates of IL-1β and TNF-α 
return to normal by 24h along with systemic concentrations.  Production of cytokines is 
enhanced despite seeing no elevation in the blood.  Buford et al (4) found no increase in serum 
levels of TNF-α or IL-1β but a significant increase in mRNA for those cytokines.  Increased 
mRNA for TNF-α has been confirmed in rats after eccentric running as well (29).  In the muscle 
tissue, cytokines can accumulate for up to 5d post exercise (6, 13).   
It is worth noting that many of the studies that reported poor plasma cytokine response (22, 41, 
50) used elbow flexors as the exercising muscle group.  It is possible that the elbow flexors were 
22 
 
just too small of a muscle group to induce enough damage in which cytokines would raise to 
discernable levels. 
 
β-Hydroxy-β-Methylbutyrate 
Leucine metabolite
 
Leucine, an essential amino acid, has several fates.   It can be incorporated into proteins, or it 
can be oxidized.  Oxidation primarily leads to the formation of Acetyl-CoA where it can be used 
as an energy source or formed into free fatty acids.  A secondary pathway is the formation of 
HMG-CoA, a necessary precursor to cholesterol. 
The pathway to cholesterol synthesis begins with the oxidation of leucine into -ketoisocaproate 
(KIC) primarily in the muscle. KIC, once transported to the liver, can be converted to acetyl-
CoA via branched chain -ketoacid dehydrogenase or it can form HMB through KIC-
Figure 1.  Overview of cholesterol synthesis from leucine.  Taken from Nissen & Abumrad (40) 
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dioxygenase.  KIC to HMB accounts for approximately 5-10% of leucine metabolism.  The Km 
for branch chain -ketoacid dehydrogenase is 10 to 40µM, which is considerably lower than the 
Km for KIC-dioxygenase (120µM).  This large difference in Km is responsible for the low 
formation of HMB from leucine. 
Evidence indicates that HMB is produced solely from leucine oxidation.  In the liver, HMB is 
converted to -hydroxy- -methyglutaryl-Coa (HMG-CoA) where it is available for use by 
HMG-CoA reductase.  Formation of mevalonate from HMG-CoA is the committed step in 
cholesterol synthesis and data demonstrate that the carbon in HMB is consistently found in de 
novo cholesterol.  Marked leucine carbons have also been shown to appear in cholesterol 
synthesis in vivo (55), verifying that leucine oxidation leads to cholesterol synthesis. 
Dose/Kinetics 
Common dosage for HMB supplementation has been 3 g/day for humans (38).  That dose 
causes a 10-fold increase in plasma HMB that peaks around 60-120 min (72).  At the typical dose 
of 3 g/day, there has been no evidence of adverse effects (15, 16, 38, 73).  Additionally, HMB 
does not impair renal function, hepatic enzyme function or immune system at doses up to 6 
g/day.  Doses beyond the typical 3 g/day have not shown any additional benefit in strength and 
lean body mass improvements (15). 
The half-life of HMB seems to be relatively low, lasting only 2.5 hours in humans (72).  
Approximately 15-30% of supplemented HMB is lost through urine with the remaining being 
retained for further metabolism.  Peak values following HMB administering are reached at 1-2 hr 
depending on the dose, and return to resting levels within 9 hrs.  Plasma HMB reaches peak 
concentration at 60 min with 3 grams and at 120 min with 1 gram.  Supplementation loading has 
been the norm (38-40, 71), with one study demonstrating a lack of significant effect without 
loading before damaging exercise (77).  Markers of muscle damage are highly variable (source), 
and could have been the reason for the lack of significance. 
Resistance Training 
One of the most widely used reasons for taking supplemented HMB is its effect on muscle 
protein breakdown.  It is commonly used by body builders and strength athletes (57).  
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Supplementation of HMB at varying dosages demonstrated that during a resistance training 
program, 3-methylhistidine is reduced in untrained individuals (38).  Muscle function gains, 
measured as peak force, were also larger with HMB supplementation.  Muscle damage 
prevention was greatest at the highest HMB dose and those subjects at the higher levels had the 
largest gains in strength.  Studies have also found creatine kinase (CK) and lactate dehydrogenase 
(LDH) to be lower in the HMB supplemented groups (15, 26, 38, 49, 56, 73) when compared to 
controls. 
Along with decreases in muscle damage, improvements in strength with untrained participants 
have been well documented (15, 26, 38, 49, 56, 73).  These studies also reported increases in lean 
body mass.  The increase in lean body mass is most likely attributed to decreased muscle 
proteolysis following EIMD.  HMB suppresses DOMS after a single bout of eccentric muscle 
contractions (70). 
Support for HMB improvements in strength with trained individuals is less than clear.  Kreider 
et al. (27) did not find an improvement with 1 RM, an increase in fat free mass, or a reduction in 
training induced muscle damage when the subjects were experienced resistance trained athletes.  
However, this study did not monitor training routines and participants were advised to maintain 
their usual routine.  Trained individuals require a larger stimulus than untrained due to their 
muscle structure.  Failing to alter their training regimen may not have evoked enough of a 
stimulus for HMB’s effects. 
In addition to Kreider et al., studies have shown a lack of change in muscle damage markers (23, 
44) suggesting that HMB does not have an effect.  Evidence that DOMS is not reduced has also 
been documented (44, 48).  Significance was not reached with these studies due to study size or 
training specificity, but most likely from the large variance seen with these measures. 
Possible Mechanisms 
One mechanism that is believed to occur is the cholesterol synthesis hypothesis.  HMB is 
converted to HMG-CoA, a rate limiting cholesterol precursor.  Because the muscle synthesizes 
its cholesterol de novo, the increased availability of HMG-CoA could provide the components for 
increased membrane integrity.  With increased cholesterol synthesis the sarcolemma will be 
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stabilized and allow for more resilience during eccentric contractions and muscle damage.  This 
theory is supported by the fact that muscle function is impaired with cholesterol synthesis 
inhibition (2).  Cholesterol synthesis inhibition also results in increased muscle damage (53)and 
possible cell death (36). 
It is also possible that HMB reduces the ubiquitin pathway for protein degradation.  The 
ubiquitin pathway is responsible for specific degradation of proteins by proteasomes within the 
cell and is common during muscular proteolysis caused by exercise (68).  HMB has been 
associated with decreased ubiquitin pathway activity in cachexic tumor bearing mice (58).  
Ubiquitin activity decreases with repeated bouts of the same exercise (75).  This suppression of 
the ubiquitin pathway could account for the lack of evidence supporting HMB having a positive 
impact with trained subjects. 
Conclusion 
It is evident that HMB can reduce proteolysis and improve muscle function.  Untrained subjects 
seem to benefit the most, but HMB can also benefit subjects who experience increased 
proteolysis.  Decreased proteolysis and muscle mass retention is not clearly understood but 
believed to occur by increasing the integrity of muscle cells and decreasing the ubiquitin pathway 
protein degradation. 
The role of HMB in inflammation resistance has not been identified.  Muscle damage and 
breakdown is associated with an inflammatory response.  It is believed that HMB can diminish 
inflammation by attenuating cytokine release, specifically the pro-inflammatory cytokines.  The 
purpose of this study is to measure cytokine response to an acute resistance training session 
when HMB is given as a supplement to reduce exercise induced muscle damage. 
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